Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXE408 in Localized Cutaneous Leishmaniasis
NCT06997159Phase 2Not yet recruiting
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LXE408 in cutaneous leishmaniasis (CL), sponsored by Drugs for Neglected Diseases initiative. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
LXE408
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT06997159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997159.